AstraZeneca and Daiichi Sankyo have reported results from the TROPION-Breast01 Phase III clinical trial of datopotamab ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...

The partners said their antibody-drug conjugate datopotomab deruxtecan didn’t extend survival in a breast cancer study, ...

AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly ...

A new AstraZeneca drug has failed to extend significantly the lives of breast cancer patients in a blow to the company’s ...

AstraZeneca said on Monday its experimental precision drug developed with Daiichi Sankyo did not significantly improve ...

AstraZeneca stock slumped Monday after its Daiichi Sankyo-partnered drug missed its mark in a study of patients with breast ...

A cancer drug being developed by AstraZeneca failed to "achieve statistical significance" in helping patients live longer ...

patients with metastatic HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial Survival results for AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan in ...

Datopotamab deruxtecan is a TROP2-directed DXd ADC engineered by Daiichi Sankyo and co-developed by AstraZeneca and Daiichi Sankyo. The data pertaining to this compound will be presented at an ...

It said the drug did not 'achieve statistical significance' in terms of the survival rates of those suffering from breast ...

AstraZeneca updated the market on two ongoing drug trials on Monday, with a key trial in breast cancer failing to improve ...